Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
MVM Partners
AddedFeb 13, 2024
UpdatedJun 28, 2026
MVM Partners

MVM Partners

Operating

MVM Life Science Partners: A global venture capital firm investing in healthcare and pharmaceutical sectors.

Location
London, Greater London, GB
Founded
2005
Firm
Compare
Portfolio
Employees
Website

Investments

Nalu Medical
Nalu Medical

Total Raised

$180.9M

Rounds

3

Series E$65MJanuary 2024
Series Unknown$104MFebruary 2022
Gynesonics
Gynesonics
Public

Total Raised

$401.8M

Rounds

16

Series Unknown$42.5MOctober 2023
CurvaFix
CurvaFix

Total Raised

$60.2M

Rounds

7

Series C$39MJuly 2023
GT Medical Technologies
GT Medical Technologies

Total Raised

$74M

Rounds

5

Series C$45MMarch 2023
Series B$16MNovember 2020
Ossio
Ossio

Total Raised

$60.5M

Rounds

3

Series C$38.5MOctober 2022
Neurolens
Neurolens

Total Raised

$186.5M

Rounds

8

Series D$67.6MSeptember 2022
Vero Biotech
Vero Biotech
Public

Total Raised

$234.6M

Rounds

7

Series E$100MDecember 2021
Inbrace
Inbrace

Total Raised

$217.6M

Rounds

7

Series D$102MSeptember 2021
Paragon 28
Paragon 28
Public

Total Raised

$223.5M

Rounds

5

Series BAugust 2020
Providence Medical Technology
Providence Medical Technology

Total Raised

$101.3M

Rounds

9

Series Unknown$25MSeptember 2018
Series E$10.5MDecember 2016
Zipline Medical
Zipline Medical

Total Raised

$56M

Rounds

7

Series F$9MJune 2018
Series E$12MJune 2017
Series D$19MJanuary 2016
Vital Connect
Vital Connect

Total Raised

$178.9M

Rounds

10

Series C$38MOctober 2017
Vertos Medical
Vertos Medical

Total Raised

$177.8M

Rounds

14

Series Unknown$28MJune 2017
Ambiopharm
Ambiopharm

Total Raised

$24M

Rounds

2

Series Unknown$24MNovember 2014
Tarsa Therapeutics
Tarsa Therapeutics
Acquired

Total Raised

$124.3M

Rounds

9

Series B$7MMay 2014
Series B$28MMarch 2012
Cara Therapeutics
Cara Therapeutics
Public

Total Raised

$517.2M

Rounds

11

Series D$4.8MMay 2012
Series D$15MJuly 2010
AccuVein
AccuVein

Total Raised

$69.3M

Rounds

6

Series B$22.5MJuly 2011
Solx
Solx
Public

Total Raised

$9.1M

Rounds

4

Series Unknown$3.7MOctober 2010